



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: samrat@bom4.vsnl.net.in

14-Feb-2019

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, February 14, 2019, have approved and took on record the Limited Review Un-Audited Standalone Financial Results for the quarter ended December 31, 2018 which are enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited


**Lalit Mehta
Managing Director**





Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar - 393 002, Gujarat
Corp Office : 701/702, Business Square, M. A. Road, Andheri (West), Mumbai - 400 058.
CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 31 December, 2018

(Rs. In Lakhs)

Particulars	Quarter ended			Year to date ended		Previous Year Ended
	31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 (a). Net Income from Sales / Services	2,737.47	2,263.19	2,508.12	7,470.76	6,607.28	9,252.01
(b). Other Operating Income	3.93	2.95	4.08	28.05	8.22	24.57
Total Income	2,741.40	2,266.14	2,512.20	7,498.81	6,615.50	9,276.58
2. Expenditure						
a) Cost of materials consumed	2,438.17	2,342.28	2,072.46	7,132.70	5,657.44	8,110.77
b) Purchase of Traded Goods	0.00	0.00	65.98	0.00	131.97	131.97
c) Change in Inventories of Finished Goods and Work-in-Progress	99.86	(225.71)	11.91	(145.75)	(1.12)	(50.56)
d) Employee Costs	31.99	28.27	28.34	87.36	88.38	129.60
e) Interest	26.55	20.79	22.73	71.67	61.57	86.35
f) Depreciation & Amortisation expense	10.63	10.49	10.92	31.37	32.33	41.22
g) Other Expenses	96.60	95.37	98.18	275.26	277.63	335.21
Total	2,703.80	2,271.49	2,310.52	7,452.61	6,248.20	8,784.56
3. Profit before exceptional & extraordinary items & tax	37.60	(5.35)	201.68	46.20	367.30	492.02
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5. Profit before extraordinary items & tax	37.60	(5.35)	201.68	46.20	367.30	492.02
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	37.60	(5.35)	201.68	46.20	367.30	492.02
8. Tax expense						
a) Current Tax	(7.80)	3.34	(59.03)	(8.06)	(105.23)	(168.94)
b) Deferred Tax	(1.47)	(7.03)	(1.88)	(14.67)	(10.65)	(1.41)
Total Tax Expense	(9.27)	(3.69)	(60.91)	(22.73)	(115.88)	(170.35)
9. Profit (Loss) for the period after tax	28.33	(9.04)	140.77	23.47	251.42	321.67
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	28.33	(9.04)	140.77	23.47	251.42	321.67
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	0.92	(0.29)	4.56	0.76	8.14	10.41
b) Diluted	0.92	(0.29)	4.56	0.76	8.14	10.41

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 31 December, 2018.
- The above results have been taken on record by the Board of Directors at its Meeting held on Thursday 14 February 2019 at the Corporate Office of the Company.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 31 December 2018 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
- The Company manufactures pharmaceutical chemicals, which is a single business segment.
- Figures for the previous period have been regrouped / reclassified, wherever necessary.

By order of the Board of Directors
For Samrat Pharmachem Limited


Rajesh Mehta
Director



Place : Mumbai
Date : 14 February 2019



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance

CA Nihar Dharod
Indirect Tax & Litigation

LIMITED REVIEW REPORT

To Board of Directors Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 31th December, 2018 and the year to date from 1st April 2018 to 31st December 2018 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financials statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.
3. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH & SAVLA LLP
Chartered Accountants
Firm Reg: No.:109364W

CA. Miral H. Nagda
(Partner)
Membership No. 108135



Place: Mumbai

Date: **14 FEB 2019**